Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 sept. 2017 08h00 HE | Source: Melinta Therapeutics

Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens

NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
05 juin 2017 12h45 HE | Source: Melinta Therapeutics

Melinta Therapeutics Demonstrates Potential of Pyrrolocytosine Candidate against Gonorrhea

New Haven, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that an oral...
21 avr. 2017 09h56 HE | Source: Melinta Therapeutics

Melinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug Design

New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that...